S2 Description

THE PURPOSE OF THIS STUDY

One common assessment of ovarian reserve is assessed through a biomarker such as a woman’s anti-Müllerian hormone (AMH) level. Changes in this indicator can signal a shift in reproductive health and fertility potential.

This study aims to evaluate the effect of COVID-19 vaccination on ovarian reserve by comparing the AMH levels in vaccinated and unvaccinated women of reproductive age. This study seeks to inform public health guidance and address vaccine-related concerns among women.

Study Description

Scope

Prospective, Observational, Descriptive

Subject Size

150 (75 treatment, 75 control)

Total Study Duration

One year or less. Participant time commitment: minimal.

Eligibility

The treatment group will be comprised of women aged 20-30 who have received at least one mRNA COVID-19 vaccine. The control group will be comprised of women aged 20-30 who have not received a mRNA COVID-19 vaccine.

Inclusion Criteria

Subjects meeting all of the following specific criteria will be considered for participation in the study:

1) Women between 20 and 30 years of age

2) Have provided Informed Consent

3) BMI of 22-27

Exclusion Criteria

1) Failure to provide informed consent

2) Current pregnancy at the time of study enrollment

3) Diagnosis or history of polycystic ovary syndrome (PCOS)

4) History of ovarian surgical procedure or hysterectomy

5) Surgical diagnosis of endometriosis

6) Undergoing or history of treatment with chemotherapy or radiation

7) Diagnosis or history of diabetes

Advanced Biological Research Group

SPIKE PROTEIN EFFECTS ON REPRODUCTIVE HEALTH

IRB APPROVAL PENDING

Introduction

THE PURPOSE OF THIS STUDY

Study Description

Do you meet the preliminary criteria detailed above?

SPIKE PROTEIN EFFECTS ON REPRODUCTIVE HEALTH

IRB APPROVAL PENDING

Introduction

THE PURPOSE OF THIS STUDY

Study Description

Do you meet the preliminary criteria detailed above?

This website uses cookies.